Chickenpox vaccine - Merck & Co

Drug Profile

Chickenpox vaccine - Merck & Co

Alternative Names: Provarivax; V211; Varicella zoster virus vaccine live - Merck & Co; Variped; Varivax; Varivax II; Zostavax

Latest Information Update: 13 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Osaka University
  • Developer CSL; Merck & Co; sanofi pasteur MSD
  • Class Varicella vaccines; Viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Herpes zoster; Varicella zoster virus infections

Most Recent Events

  • 29 May 2018 Merck terminates a phase III trial as the PI has terminated the study at this time for Herpes-zoster and Varicella zoster virus infections (Prevention) in USA (SC) (NCT02960399)
  • 17 Oct 2017 Merck initiates enrolment in the V210-A03 phase III trial for Varicella zoster virus infections (Prevention) in USA (NCT03239873)
  • 08 Aug 2017 Merck Sharp & Dohme plans a phase III trial for Varicella zoster virus infections (Prevention, In In infants) (NCT03239873)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top